子宮筋腫治療の世界市場規模：治療タイプ別、タイプ別、エンドユーザー別、地域別、範囲および予測

子宮筋腫治療の市場規模と予測

子宮筋腫治療市場規模は、2023年に48億7,000万米ドルと評価され、2024年から2031年にかけて9.30%のCAGRで成長し、2031年には107億1,000万米ドルに達すると予測されます。子宮筋腫治療は、子宮筋腫として知られる子宮内の非がん性増殖に対処するために調整された様々なソリューションによって特徴付けられます。子宮筋腫を効果的に管理し、患者の全体的な生活の質を高めるために、集束超音波のような低侵襲的処置から子宮筋腫核出術のような大掛かりな外科的介入まで、多様な選択肢のツールボックスがこの市場で提供されています。

女性は、子宮筋腫に関連する身体的症状や関連する不安の緩和を通じて、この市場から直接的な恩恵を受ける。一方、専門的な機器や処置が病院やクリニックなどのヘルスケア機関に提供されることで、この一般的な女性の健康問題への対処能力が強化されます。

子宮筋腫は、子宮にできる最も一般的な良性腫瘍で、大きさはさまざまで、生殖年齢にある女性の約20％～40％が罹患するという特徴があります。多量の月経出血、骨盤痛、頻尿、その他の不快感を含む症状が、罹患者に経験されます。ホルモン標的薬、塞栓術、MRIガイド下集束超音波手術（FUS）、場合によっては子宮摘出術を含む治療アプローチは、世界中の何百万人もの女性に影響を与えています。

子宮筋腫治療の世界市場力学

子宮筋腫治療市場を形成している主な市場力学

主な市場促進要因

子宮筋腫の有病率の増加：

女性の加齢に伴う子宮筋腫の診断率の増加は、出産遅延、肥満率の上昇、診断手法の強化などの要因に影響される調査によって指摘されています。

低侵襲手術に対する需要の高まり：

子宮動脈塞栓術や集束超音波アブレーションなど、侵襲が少なく回復が早い治療法は、従来の手術に代わる望ましい選択肢として女性からますます支持されています。

技術の進歩：

子宮筋腫治療の領域における絶え間ない技術革新により、MRIガイド下集束超音波治療やレーザー焼灼術のような低侵襲の新しい治療法が登場し、より安全で効果的な治療選択肢が提供されています。

ヘルスケアへのアクセスの拡大：

一部の地域では保険適用や政府の取り組みが強化され、診断と治療の両方へのアクセシビリティが拡大し、市場の拡大を後押しするとともに、より幅広い患者層のヘルスケアニーズに対応しています。

主な課題

コストの障壁：

特に保険適用が限定的な地域や社会経済的地位の低い個人にとっては、処置や専門機器に関連する費用が大きな障害となっており、必要な治療へのアクセスを妨げています。

認知度の課題：

子宮筋腫および利用可能な治療選択肢に対する女性およびヘルスケア専門家の理解が限られているため、診断が遅れ、早期介入への取り組みが妨げられ、子宮筋腫の影響が悪化する可能性があります。

アクセスの制限：

有資格の婦人科医や専門治療センターの分布に格差があり、特に農村部ではそれが顕著で、治療を求める患者に障害をもたらし、適切な医療を受ける能力を制限していることが観察されます。

専門医への限られたアクセス：

有資格の婦人科医や専門治療センターが不均等に存在し、特に地方で顕著であることが、患者が治療を受ける際の障害となっていることが指摘されています。

主な動向

低侵襲手術：

UAE、MRgFUS、ロボット手術のような分野の成長は、患者中心の治療を目指す広範な傾向を反映した、より低侵襲な選択肢への嗜好が原動力となっています。

治療の個別化：

年齢、妊孕性の目標、症状の重さなど、個々の要素に基づいて治療計画を調整することで、治療効果と患者の満足度を高める精密医療のアプローチが推進されています。

技術の進歩：

AIを活用した診断、ロボット支援手術、生体適合材料などの開発により、精度の向上、リスクの軽減、回復期間の短縮の可能性が認められ、子宮筋腫治療技術の大きな進歩を意味します。

妊孕性温存の焦点：

卵巣組織温存を伴う子宮筋腫核出術のように、生殖能力への影響を最小限に抑える子宮筋腫治療への需要の高まりは、患者にとって生殖能力を温存する選択肢が重視されるようになっていることを浮き彫りにしています。

目次

第1章 世界の子宮筋腫治療市場：イントロダクション

• 市場概要
• 調査範囲
• 前提条件

第2章 エグゼクティブサマリー

第3章 VERIFIED MARKET RESEARCHの調査手法

• データマイニング
• バリデーション
• 一次インタビュー
• データソース一覧

第4章 子宮筋腫治療の世界市場展望

• 概要
• 市場力学
  • 促進要因
  • 抑制要因
  • 機会
• ポーターのファイブフォースモデル
• バリューチェーン分析

第5章 子宮筋腫治療の世界市場：治療タイプ別

• 概要
• 外科手術
  • 子宮筋腫核出術
  • 子宮内膜焼灼術
  • 子宮摘出術
• ホルモン療法
  • 黄体ホルモン
  • GnRHアゴニスト
• MRIガイド下集束超音波手術（FUS）
• 塞栓術
• その他

第6章 子宮筋腫治療の世界市場：タイプ別

• 概要
• 粘膜下筋腫
• 硬膜内子宮筋腫
• 血腫型子宮筋腫
• 漿膜下子宮筋腫

第7章 子宮筋腫治療の世界市場：エンドユーザー別

• 概要
• 病院
• 診療所
• 外来手術センター
• 婦人科医

第8章 子宮筋腫治療の世界市場：地域別

• 概要
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • その他欧州
• アジア太平洋
  • 中国
  • 日本
  • インド
  • その他アジア太平洋地域
• 世界のその他の地域
  • ラテンアメリカ
  • 中東・アフリカ

第9章 世界の子宮筋腫治療市場：競合情勢

• 概要
• 各社の市場ランキング
• 主な発展戦略

第10章 企業プロファイル

• Boston Scientific Corporation
• GE Healthcare
• Siemens Medical Solutions
• Cooper Surgical
• F. Hoffmann-La Roche Ltd.

第11章 付録

• 関連調査

Uterine Fibroids Treatment Market Size And Forecast

Uterine Fibroids Treatment Market size is valued at USD 4.87 Billion in 2023 and is projected to reach USD 10.71 Billion by 2031, growing at a CAGR of 9.30% from 2024 to 2031. The Uterine Fibroids Treatment is characterized by a variety of solutions tailored to address non-cancerous growths, known as uterine fibroids, within the uterus, which are often associated with discomfort, heavy bleeding, and fertility concerns for affected women. A diverse toolbox of options, ranging from minimally invasive procedures like focused ultrasound to more extensive surgical interventions such as myomectomy, is offered by this market, to effectively manage fibroids and enhance the overall quality of life for patients.

Women are directly benefited by this market through the alleviation of physical symptoms and related anxieties associated with fibroids, while specialized equipment and procedures are provided to healthcare institutions like hospitals and clinics, thereby enhancing their ability to address this prevalent women's health issue.

Uterine fibroids, the most common benign tumors in the uterus, are characterized by varying sizes and affect approximately 20%-40% of women during their reproductive years. Symptoms, including heavy menstrual bleeding, pelvic pain, frequent urination, and other discomforts, are experienced by affected individuals. Treatment approaches, encompassing hormone-targeting medications, embolization, MRI-guided focused ultrasound surgery (FUS), and in some cases, hysterectomy, impact millions of women worldwide.

Global Uterine Fibroids Treatment Market Dynamics

The key market dynamics that are shaping the Uterine Fibroids Treatment Market include:

Key Market Drivers

Increased Prevalence of Uterine Fibroids:

A growing diagnosis rate of uterine fibroids among women as they age is indicated by research, influenced by factors such as delayed childbearing, escalating obesity rates, and enhanced diagnostic methodologies.

Growing Demand for Minimally Invasive Procedures:

Less invasive and speedier recovery alternatives, including uterine artery embolization and focused ultrasound ablation, are increasingly favored by women as preferable alternatives to conventional surgeries.

Advancements in Technology:

Continuous innovation in the realm of uterine fibroid treatment has led to the emergence of novel, minimally invasive procedures like MRI-guided focused ultrasound and laser ablation, offering safer and more efficacious therapeutic options.

Expansion of Healthcare Accessibility:

Enhanced insurance coverage and governmental initiatives in select regions are widening the accessibility to both diagnosis and treatment, propelling market expansion and catering to the healthcare needs of a broader patient demographic.

Key Challenges

Cost Barriers:

The cost associated with procedures and specialized equipment is seen as a significant hindrance, particularly in regions with limited insurance coverage or for individuals with lower socioeconomic status, thereby impeding access to necessary treatment.

Awareness Challenges:

Limited understanding of fibroids and the available treatment options among both women and healthcare professionals can result in delayed diagnosis and hinder efforts for early intervention, exacerbating the impact of the condition.

Access Limitations:

Disparities in the distribution of qualified gynecologists and specialized treatment centers, particularly evident in rural areas, are observed to create obstacles for patients seeking care, thus limiting their ability to access appropriate medical attention.

Limited Access to Specialists:

Unequal availability of qualified gynecologists and specialized treatment centers, particularly pronounced in rural areas, is noted to contribute to barriers in accessing care for patients.

Key Trends

Minimally Invasive Procedures:

Growth in segments like UAE, MRgFUS, and robotic surgery is driven by a preference for less invasive options, reflecting a broader trend toward patient-centered care.

Treatment Personalization:

Precision medicine approaches are promoted through tailoring treatment plans based on individual factors such as age, fertility goals, and symptom severity, enhancing treatment efficacy and patient satisfaction.

Technological Advancements:

Precision improvement, risk reduction, and potential recovery time shortening are observed with ongoing developments in AI-powered diagnostics, robotic-assisted surgery, and biocompatible materials, signifying significant strides in fibroid treatment technology.

Fertility Preservation Focus:

An increasing demand for fibroid treatments minimizing the impact on reproductive potential, like myomectomy with ovarian tissue preservation, highlights a growing emphasis on preserving fertility options for patients.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

Global Uterine Fibroids Treatment Market Regional Analysis

Here is a more detailed regional analysis of the Uterine Fibroids Treatment Market:

North America

A high prevalence of uterine fibroids in North America, particularly the United States, is observed compared to other regions, with factors like lifestyle choices and improved diagnostic techniques being attributed.

The financial burden of fibroid treatment for many individuals is eased by the well-developed healthcare infrastructure in North America, including advanced medical facilities and skilled specialists, along with widespread health insurance coverage.

Continuous innovation in the development of novel treatment options for uterine fibroids is driven by North America's role as a hub for research and development, positioning regional companies as market leaders. This enables the region to hold a major share in the market.

Asia Pacific

A rise in uterine fibroid prevalence in the Asia Pacific is anticipated due to factors such as delayed childbearing and increasing obesity rates, prompting earlier diagnosis and treatment seeking among women and healthcare professionals.

Investments in healthcare infrastructure, including the establishment of more hospitals and clinics equipped for advanced fibroid treatments, are being made in many Asian countries as a result of rapid economic development, with rising disposable incomes facilitating this development.

The Asia Pacific region's vast population size, particularly in countries like China and India, presents a significant untapped market for fibroid treatment solutions, attracting attention from global players and driving market growth as healthcare access and affordability increase.

Global Uterine Fibroids Treatment Market Segmentation Analysis

The Global Uterine Fibroids Treatment Market is segmented on the basis of Treatment Type, Type, End Users, and Geography.

Uterine Fibroids Treatment Market, By Treatment Type

• Surgical
• Myomectomy
• Endometrial Ablation
• Hysterectomy
• Hormonal
• Progestins
• GnRH Agonists
• MRI-guided Focused Ultrasound Surgery (FUS)
• Embolization
• Others

Based on Treatment Type, The market is segmented into Surgical, Hormonal, Embolization, MRI-guided Focused Ultrasound Surgery (FUS), and Others. Of these, the largest market share is commanded by the surgical segment, primarily due to its effectiveness in addressing fibroids through procedures like myomectomy and hysterectomy. Patients are provided with tangible relief from symptoms and their quality of life is improved through direct removal or ablation of fibroids offered by surgical interventions. The significance of surgical options in managing uterine fibroids is underscored by this dominance, highlighting their widespread acceptance among patients and healthcare providers.

Uterine Fibroids Treatment Market, By Type

• Submucosal Fibroids
• Intramural Fibroids
• Pedunculated Fibroids
• Subserosal Fibroids

Based on Type, The market is segmented into Submucosal Fibroids, Intramural Fibroids, Pedunculated Fibroids, and Subserosal Fibroids. Among the types, the highest market share in the Uterine Fibroids Treatment Market is typically held by intramural fibroids. This is because intramural fibroids are the most common type, growing within the muscular wall of the uterus. The pain caused by these are shifting the focus on various treatment options depending on severity and patient preferences.

Uterine Fibroids Treatment Market, By End Users

• Hospitals
• Clinics
• Ambulatory Surgical Centers
• Gynecologists

Based on End Users, The market is segmented into Hospitals, Clinics, Ambulatory Surgical Centers, and Gynecologists. The highest market share in the Uterine Fibroids Treatment Market is typically held by hospitals. This is primarily because hospitals function as primary healthcare facilities where a wide range of medical services, including fibroid treatments, are provided. Hospitals are often equipped with specialized departments and equipment dedicated to gynecological procedures, making them a preferred choice for patients seeking comprehensive fibroid treatment.

Key Players

• The "Global Uterine Fibroids Treatment Market" study report will provide valuable insight with an emphasis on the global market including some of the major players such as
• Boston Scientific Corporation, GE Healthcare, Siemens Medical Solutions, Cooper Surgical, and F. Hoffmann-La Roche Ltd.

Our market analysis includes a section specifically devoted to such major players, where our analysts give an overview of each player's financial statements, product benchmarking, and SWOT analysis. Key development strategies, market share analysis, and market positioning analysis of the aforementioned players globally are also included in the competitive landscape section.

• Uterine Fibroids Treatment Market Recent Developments
• In October 2023, a partnership was formed between Siemens Healthineers AG and IZI Medical Products to integrate the Fibroid Finder software with the Acessa procedure, to enhance treatment planning for fibroids.
• In October 2023, the Sono Site iViz ultrasound system was launched by Olympus Corporation, featuring enhanced functionalities designed for diagnosing and guiding minimally invasive fibroid treatments.
• In October 2023, CE Mark approval was received by Boston Scientific Corporation for its EMPOWER MRgFUS system, thereby expanding its portfolio of minimally invasive fibroid treatment options in Europe.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL UTERINE FIBROIDS TREATMENT MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL UTERINE FIBROIDS TREATMENT MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL UTERINE FIBROIDS TREATMENT MARKET, BY TREATMENT TYPE

• 5.1 Overview
• 5.2 Surgical
  • 5.2.1 Myomectomy
  • 5.2.2 Endometrial ablation
  • 5.2.3 Hysterectomy
• 5.3 Hormonal
  • 5.3.1 Progestins
  • 5.3.1 GnRH agonists
• 5.4 MRI-guided Focused Ultrasound Surgery (FUS)
• 5.5 Embolization
• 5.6 Others

6 GLOBAL UTERINE FIBROIDS TREATMENT MARKET, BY TYPE

• 6.1 Overview
• 6.2 Submucosal Fibroids
• 6.3 Intramural Fibroids
• 6.4 Pedunculated Fibroids
• 6.5 Subserosal Fibroids

7 GLOBAL UTERINE FIBROIDS TREATMENT MARKET, BY END USERS

• 7.1 Overview
• 7.2 Hospitals
• 7.3 Clinics
• 7.4 Ambulatory Surgical Centers
• 7.5 Gynecologists

8 GLOBAL UTERINE FIBROIDS TREATMENT MARKET, BY GEOGRAPHY

• 8.1 Overview
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
  • 8.2.3 Mexico
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 U.K.
  • 8.3.3 France
  • 8.3.4 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Rest of Asia Pacific
• 8.5 Rest of the World
  • 8.5.1 Latin America
  • 8.5.2 Middle East And Africa

9 GLOBAL UTERINE FIBROIDS TREATMENT MARKET COMPETITIVE LANDSCAPE

• 9.1 Overview
• 9.2 Company Market Ranking
• 9.3 Key Development Strategies

10 COMPANY PROFILES

• 10.1 Boston Scientific Corporation
  • 10.1.1 Overview
  • 10.1.2 Financial Performance
  • 10.1.3 Product Outlook
  • 10.1.4 Key Developments
• 10.2 GE Healthcare
  • 10.2.1 Overview
  • 10.2.2 Financial Performance
  • 10.2.3 Product Outlook
  • 10.2.4 Key Developments
• 10.3 Siemens Medical Solutions
  • 10.3.1 Overview
  • 10.3.2 Financial Performance
  • 10.3.3 Product Outlook
  • 10.3.4 Key Developments
• 10.4 Cooper Surgical
  • 10.4.1 Overview
  • 10.4.2 Financial Performance
  • 10.4.3 Product Outlook
  • 10.4.4 Key Developments
• 10.5 F. Hoffmann-La Roche Ltd.
  • 10.5.1 Overview
  • 10.5.2 Financial Performance
  • 10.5.3 Product Outlook
  • 10.5.4 Key Developments

11 Appendix

• 11.1 Related Research